Point-of-Care Testing in Hypercoagulable Conditions Managed With Warfarin: A Review : Point of Care

Secondary Logo

Journal Logo

Review Article

Point-of-Care Testing in Hypercoagulable Conditions Managed With Warfarin

A Review

Faber, Nicholas N. BS; Bulmer, Shanaya C.; Gandhi, Mona A. PharmD; Nagel, Angela K. PharmD, BCPS, BC-ADM

Author Information
Point of Care: The Journal of Near-Patient Testing & Technology 19(4):p 101-105, December 2020. | DOI: 10.1097/POC.0000000000000215



The aim of this review was to summarize new data on the use of international normalized ratio (INR) point-of-care testing (POCT) devices in hypercoagulable disease states such as antiphospholipid syndrome (APS) and those with left ventricular assist devices (LVADs).


PubMed and Google Scholar were searched for keywords relating to warfarin, point-of-care testing, and hypercoagulable conditions. Intensive care unit studies and articles not in English were excluded.


Four recent studies examining 3 different POCT devices in patients with APS and 2 for patients with LVADs were found. The studies compared devices against laboratory INRs as a standard or against another POCT device to determine device agreeability or bias. Results showed that CoaguChek XS does not correlate well with laboratory INRs in patients with APS but is acceptable in LVAD patients. Coagsense and ProTime InRhythm correlated well with laboratory INR values in APS patients.


Coagsense and ProTime InRhythm may be acceptable POCT devices to use for APS patients, whereas CoaguChek XS is not acceptable. In LVAD patients, CoaguChek XS is acceptable because it correlates well with laboratory INR values.

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid